New Trends in Dyslipidemia Treatment

Jang, Albert Youngwoo; Lim, Soo; Jo, Sang‐Ho; Han, Seung Hwan; Koh, Kwang Kon

doi:10.1253/circj.cj-20-1037

Cited by 26 publications

(20 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The availability and use of lipid-lowering medication, such as statin therapy and ezetimibe, or proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, significantly reduces lipid levels. In turn, reducing the number of patients with hyperlipidemia and therefore the risk of an acute cardiovascular event ( 40 , 41 ). Statin therapies also generally reduced the risk of an acute cardiovascular event by 25 to 45%, which was noted over 5 years of follow-ups ( 6 ).…”

Section: Discussionmentioning

confidence: 99%

Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jiang

Lin

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

BackgroundPatients with metabolic syndrome (MetS) have increased cardiovascular risk. Capsaicin (CAP) has been shown to reduce lipids, but efficacy for patients with MetS is unknown.MethodsA systematic review was performed according to PRISMA guidelines, to compare the effects of CAP against a placebo. Differences in the weight mean difference (WMD) with 95% confidence intervals (95% CI) were then pooled using a random effects model.ResultsNine randomized controlled trials including 461 patients were identified in the overall analysis. CAP significantly decreased total cholesterol (TC) (WMD = −0.48, 95% CI: −0.63 to −0.34, I2= 0.00%) and low-density lipoprotein cholesterol (LDL-C) (WMD = −0.23, 95% CI: −0.45 to −0.02, I2 = 68.27%) among patients with MetS. No significant effects of CAP were found on triglycerides (TG) or high-density lipoprotein cholesterol (HDL-C) (WMD = −0.40, 95% CI: −1.50 to 0.71, I2 = 98.32%; WMD = −0.08, 95% CI: −0.21 to 0.04, I2 = 86.06%). Subgroup analyses indicated that sex and intervention period were sources of heterogeneity. The results revealed that CAP decreased TG levels in women (WMD = −0.59, 95% CI: −1.07 to −0.10) and intervention period <12 weeks (WMD = −0.65; 95% CI: −1.10 to −0.20). And there was no potential publication bias according to funnel plot, Begg' test and Egger regression test.ConclusionsCAP supplementation is a promising approach to decreasing TC and LCL-C levels in patients with MetS. However, short-term (<12 weeks) use of CAP in women may also reduce TG levels.Systematic Review RegistrationIdentifier: CRD42021228032.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jiang

Lin

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

show abstract

“…But around 40% of total number of patients receiving statins experience cardiovascular disease [30,31]. They have some other notable side effects like insulin resistance and myopathy or myalgia [32]. Studies show Rosuvastatin is more efficacious in improving lipid profile, atherogenic index and modulation of inflammatory biomarkers in dyslipidemic T2D patients compared with Atorvastatin.…”

Section: Current Trends In Research On Dyslipidaemiamentioning

confidence: 99%

“…Recently statins have been used with Ezetimibe or proprotein convertase subtilisin-kexin type 9 (PCSK-9) inhibitors to reduce LDL-C levels further but still a significant residual risk of CVD exist [35]. The protein named as Niemann-Pick C1-like 1 protein plays a key role in cholesterol absorption from the intestines and it is targeted upon by Ezetimibe [32]. Co-administration of ezetimibe with statins in a study on hypercholestraemia patients significantly decreased CRP and insulin levels, increased adiponectin levels and insulin sensitivity, and reduced visceral fat and blood pressure [36].…”

Section: Current Trends In Research On Dyslipidaemiamentioning

confidence: 99%

“…IONIS-APO (a) and Inclisiran respectively. This is a revolutionary advancement that promises to reduce the required doses, make the drugs safer and to improve the outcome of treatment [32]. As far as modern medicine is concerned, statins had been the mainstay of treatment in last many years despite of often resulting in side effects and not being able to prevent cardiovascular diseases.…”

Section: Current Trends In Research On Dyslipidaemiamentioning

confidence: 99%

See 1 more Smart Citation

Scientometric Study on Dyslipidaemia

Phull

Deshpande

Phull

2021

JPRI

View full text Add to dashboard Cite

Dyslipidaemia an ever increasing menace emerging out of present lifestyle, is one of the major risk factors for developing Cardio-vascular abnormalities like Coronary Artery Disease (CAD), Myocardial infarction (MI), Cardiac arrest and is often associated with other metabolic disorders. Clinicians across the globe are trying hard to combat it. We have presented a Scientometric analysis of dyslipidaemia which includes Ayurvedic perspective also. Objective: In this study we intended to study detailed Scientometric and Bibliometric study on dyslipidaemia literature. Materials and methods: The data was collected using databases of Science- direct and Scopus, using the keywords ‘Dyslipidaemia’, ‘Dyslipidaemia in Ayurveda’, ‘Dyslipidaemia in India’,‘Medoroga in Ayurveda’ and ‘Medoraga in India’. Results: A total of 85,500 items were retrieved from ‘science direct’ website, where majority of them were research articles and maximum publications were from the last decade indicating the recent enhancement in prevalence and awareness. A volley of research papers have come up with multiple approaches which include modern pharmacological measures, Ayurveda remedies and other herbal medicines along with non-pharmacological approaches like Yoga and Pranayama. Newer therapeutic agents like Ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, PCSK9 small interference RNA (siRNA), and bempedoic acid, when added to the commonly used statin therapy have shown additional improvement to CV outcomes. Recent advances have come up with hepatocyte-specific targeting modifications and have shown promising lipid lowering effects. Conclusion: Our study was probably the first such kind of work in field of dyslipidaemia which includes publications related to Ayurveda and other herbal remedies also. It shows the ever rising trends in the publications related to dyslipidaemia and its relation to other metabolic disorders in recent years. The major concern is the progression in cases of dyslipidaemia and its cardiovascular outcomes despite of having substantial research work and awareness in different streams of medicine. We must focus on the multifactorial approach encouraging behavioural, dietary and pharmacological control of cholesterol and sensitize the masses about its serious consequences. A cumulative approach including modern advances with much safer herbal remedies and practice of Yogasana and Pranayama is the need of hour and may probably bring the best solution.

show abstract

“…The treatment of dyslipidemia is dominated by statins, used as monotherapy or in combination with ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and fibrates, which have been demonstrated to be effective in lipid-lowering and cardiovascular risk reduction. Statins act by decreasing the cellular cholesterol content by selectively inhibiting the enzyme HMG-CoA reductase, limiting cholesterol biosynthesis, and lowering hepatic cholesterol concentrations [ 4 ]; thus, it reduces major vascular events, major coronary events and coronary revascularizations, and ischemic stroke [ 5 ]. However, statins are often associated with adverse effects such as liver toxicity and myopathy.…”

Section: Introductionmentioning

confidence: 99%

Molecular Mechanism of Crataegi Folium and Alisma Rhizoma in the Treatment of Dyslipidemia Based on Network Pharmacology and Molecular Docking

Wang

Zhang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Dyslipidemia has become a critical global issue for public health, with elevating prevalence and morbidity closely related to many cardiovascular diseases (CVD) with high incidence rates. Crataegi Folium (known as Shanzhaye in China, SZ, the leaves of Crataegus pinnatifida Bge. var. major N.E. Br. or Crataegus pinnatifida Bge) and Alisma rhizoma (known as Zexie in China, ZX, the dried tuber of Alisma orientale (Sam.) Juzep or Alisma plantago-aquatica Linn), a classic combination of herbs, have been widely used to treat dyslipidemia. However, the therapeutic mechanism of this pair still remains unclear. Hence, this study aimed to elucidate the molecular mechanism of the Shanzhaye-Zexie herb pair (SZHP) in the treatment of dyslipidemia with the use of a network pharmacology analysis approach. Methods. Active compounds, targets of the SZHP, and targets for dyslipidemia were screened based on the public database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were performed on the database for annotation, visualization, and integrated discovery (DAVID 6.8). The compound-target-disease-pathway network was visualized using the Cytoscape software, and SYBYL was used for molecular docking. Results. Twelve active compounds in the SZHP were screened out, which were closely connected to 186 dyslipidemia-related targets. The network analysis revealed that sitosterol, stigmasterol, isorhamnetin, kaempferol, and quercetin might be candidate agents and CCND1, CASP3, HIF1A, and ESR1 genes were potential drug targets. GO analysis revealed 856 biological processes (BP), 139 molecular functions (MF), and 89 cellular components (CC). The KEGG pathway enrichment analysis indicated that the lipid level and atherosclerosis might influence the treatment of dyslipidemia. Molecular docking showed that quercetin bound well to CCND1, HIF1A, MYC, AKT1, and EGFR genes. These findings were in accord with the prediction obtained through the network pharmacology approach. Conclusions. This study revealed the primary pharmacological effects and relevant mechanisms of the SZHP in treating dyslipidemia. Our findings may facilitate the development of the SZHP or its active compounds as an alternative therapy for dyslipidemia. Still, more pharmacological experiments are needed for verification.

show abstract

New Trends in Dyslipidemia Treatment

Cited by 26 publications

References 74 publications

Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Lipid-Lowering Efficacy of the Capsaicin in Patients With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Scientometric Study on Dyslipidaemia

Molecular Mechanism of Crataegi Folium and Alisma Rhizoma in the Treatment of Dyslipidemia Based on Network Pharmacology and Molecular Docking

Contact Info

Product

Resources

About